The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.
Aged
Alleles
Case-Control Studies
Cigarette Smoking
/ adverse effects
Confounding Factors, Epidemiologic
DNA Repair
DNA-Binding Proteins
/ genetics
Endonucleases
/ genetics
Female
Genetic Predisposition to Disease
Genotype
Humans
Lung Neoplasms
/ epidemiology
Male
Middle Aged
Polymorphism, Single Nucleotide
Risk Assessment
/ methods
Risk Factors
Taiwan
/ epidemiology
ERCC1
Taiwan
genotype
lung cancer
polymorphism
smoking
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
18
05
2020
revised:
24
05
2020
accepted:
25
05
2020
entrez:
30
8
2020
pubmed:
30
8
2020
medline:
6
5
2021
Statut:
ppublish
Résumé
The study aims to evaluate the contribution of excision repair cross-complementing group 1 (ERCC1), which plays an important role in genome integrity maintenance, to lung cancer risk. ERCC1 rs11615 and rs3212986 genotypes were identified by polymerase chain reaction-restriction fragment length polymorphism analysis and their association with lung cancer risk was examined among 358 lung cancer patients and 716 controls. The proportions of CC, CT and TT for the rs11615 genotype were 43.6%, 41.6% and 14.8% in the case group and 50.0%, 41.1% and 8.9% in the control group, respectively (p for trend=0.0082). Allelic analysis showed that ERCC1 rs11615 T-allele carriers have a 1.32-fold higher risk of lung cancer than wild-type C-allele carriers [95%confidence interval (CI)=1.09-1.60, p=0.0039]. In addition, a significant interaction between the rs11615 genotype and smoking status was observed. The T allele of ERCC1 rs11615 jointly with smoking habits may contribute to a higher lung cancer risk in Taiwan.
Sections du résumé
BACKGROUND
BACKGROUND
The study aims to evaluate the contribution of excision repair cross-complementing group 1 (ERCC1), which plays an important role in genome integrity maintenance, to lung cancer risk.
MATERIALS AND METHODS
METHODS
ERCC1 rs11615 and rs3212986 genotypes were identified by polymerase chain reaction-restriction fragment length polymorphism analysis and their association with lung cancer risk was examined among 358 lung cancer patients and 716 controls.
RESULTS
RESULTS
The proportions of CC, CT and TT for the rs11615 genotype were 43.6%, 41.6% and 14.8% in the case group and 50.0%, 41.1% and 8.9% in the control group, respectively (p for trend=0.0082). Allelic analysis showed that ERCC1 rs11615 T-allele carriers have a 1.32-fold higher risk of lung cancer than wild-type C-allele carriers [95%confidence interval (CI)=1.09-1.60, p=0.0039]. In addition, a significant interaction between the rs11615 genotype and smoking status was observed.
CONCLUSION
CONCLUSIONS
The T allele of ERCC1 rs11615 jointly with smoking habits may contribute to a higher lung cancer risk in Taiwan.
Identifiants
pubmed: 32859635
pii: 17/5/571
doi: 10.21873/cgp.20213
pmc: PMC7472448
doi:
Substances chimiques
DNA-Binding Proteins
0
ERCC1 protein, human
EC 3.1.-
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-577Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Gene. 2014 Sep 10;548(1):1-5
pubmed: 24861646
Asian Pac J Cancer Prev. 2016;17(3):1369-72
pubmed: 27039774
In Vivo. 2020 May-Jun;34(3):1117-1123
pubmed: 32354900
Ann Oncol. 2010 Mar;21(3):535-539
pubmed: 19850635
Pharmacogenomics J. 2019 Apr;19(2):164-177
pubmed: 29662106
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
Br J Cancer. 2013 Jul 9;109(1):68-75
pubmed: 23807173
Int J Oncol. 2000 Mar;16(3):555-60
pubmed: 10675489
Int J Clin Exp Pathol. 2015 Nov 01;8(11):15065-71
pubmed: 26823845
BMC Pharmacol Toxicol. 2015 Feb 27;16:2
pubmed: 25881102
Anticancer Res. 2018 Oct;38(10):5671-5677
pubmed: 30275186
Cancer Med. 2020 Jan;9(2):605-614
pubmed: 31797573
Br Med J. 1950 Sep 30;2(4682):739-48
pubmed: 14772469
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):287-292
pubmed: 31243109
Eur Respir J. 2016 Sep;48(3):889-902
pubmed: 27174888
Onco Targets Ther. 2019 Aug 09;12:6237-6244
pubmed: 31496727
Br J Cancer. 2008 Oct 7;99(7):1050-5
pubmed: 18797464
Mutat Res. 2014 Jan;759:37-44
pubmed: 24220697
Cancer Treat Rev. 1998 Oct;24(5):331-44
pubmed: 9861196
Cancer Biomark. 2009;5(4):159-65
pubmed: 19729825
Clin Cancer Res. 2005 Sep 1;11(17):6212-7
pubmed: 16144923
Mol Cell Biol. 2000 Nov;20(21):7980-90
pubmed: 11027268
Anticancer Res. 2018 Jan;38(1):253-257
pubmed: 29277780
Gynecol Oncol. 2013 Aug;130(2):377-82
pubmed: 23632208
J Transl Med. 2014 Sep 25;12:272
pubmed: 25253066
Chin J Physiol. 2019 Sep-Oct;62(5):210-216
pubmed: 31670285
J Pathol. 2018 Oct;246(2):134-140
pubmed: 29952003
Mutat Res. 1999 Mar 8;424(1-2):207-19
pubmed: 10064862
Adv Exp Med Biol. 2016;893:43-57
pubmed: 26667338
Jpn J Clin Oncol. 2010 Oct;40(10):954-60
pubmed: 20462983
Anticancer Res. 2010 Apr;30(4):1195-9
pubmed: 20530427
Anticancer Res. 2019 Oct;39(10):5375-5380
pubmed: 31570432
J Cancer. 2014 May 02;5(6):425-32
pubmed: 24847383
Anticancer Res. 2018 Nov;38(11):6321-6327
pubmed: 30396953
Pharmacogenet Genomics. 2013 Nov;23(11):597-604
pubmed: 23962907
Cancer Invest. 2008 Apr-May;26(3):262-8
pubmed: 18317967
Head Neck. 2019 Aug;41(8):2704-2715
pubmed: 30973677
Tumori. 2016 Aug 3;102(4):367-75
pubmed: 27396427
Oncol Lett. 2015 Oct;10(4):1997-2002
pubmed: 26622786
Chin J Physiol. 2009 Dec 31;52(6):411-8
pubmed: 20337148
Cancer Genomics Proteomics. 2018 May-Jun;15(3):207-212
pubmed: 29695403